CONFERENCE DAY TWO
MAY 20, 2025
7:30 am
One-on-One Partnering portal meeting schedule starts, to sit down with key contacts up to an hour before day two starts.
8:25 am Chair’s Opening Remarks
Developing Molecular Glue Degraders for Disease Targets not Druggable by PROTACs
Developing Molecular Glue Degraders for Disease Targets not Druggable by PROTACs
8:30 am Identifying Basal Ligase-Substrate Interactions for Molecular Glue Discovery
Synopsis
• Introducing AlphaSeq, enabling large-scale mapping of basal protein-protein interactions between therapeutically relevant substrates and a diverse repertoire of ligases and chaperones, providing a rich starting dataset for molecular glue discovery
• Sharing how machine learning models can integrate aggregate PPI data to predict neosubstrates and can leverage mutation analysis and structural insights to strengthen binding interfaces and uncover new therapeutic opportunities
• Showing how potentially gluable weak basal interactions can be leveraged for small molecule screening, using the AlphaSeq platform or complementary hit identification approaches
8:50 am Panel Discussion: Moving from Phenotypic Screening to Target Based Discovery
Synopsis
• Overview of panellist’s platform technologies to identify glues and degraders including scientific or technical hurdles platforms address
• How can we combat the diversity in compounds when rationally designing novel candidates?
• What features define a protein as ligandable within a target space?
• How can we provide systematic and scalable screening panels; the debate between biochemical, phenotypical or computational assays
9:20 am
Morning Break & Networking
9:30 am
One-to-One Partnering Meeting Opportunity
New Platforms for Protein Stabilization & Homeostasis: Demonstrating a Pharmacological Audit Trail
New Platforms for Protein Stabilization & Homeostasis: Demonstrating a Pharmacological Audit Trail
11:10 am Developing Optimized Folding Interfering Degraders Targeting Cyclin D1
Synopsis
• Providing an overview of folding interference as a new modality to induce the degradation of a target protein
• Demonstrating that folding interfering degraders (FIDs) can be optimized to achieve high potency and desirable ADME properties
• Showing in vitro and in vivo characterization of FIDs acting on Cyclin D1
11:30 am Phosphorylation-Inducing Chimeric Small Molecules – Pairing Kinases with Induced Proximity
Synopsis
• Enabling precise phosphorylation, an important post-translational modification that controls protein function, including activation, stabilization, trafficking, inactivation, and degradation
• Leveraging approach for treating cancer, and other critical immune, metabolic, and rare diseases
• Discussing collaborations to date, and future collaborations
11:50 am Expanding the Realm of Proximity to Achieve Biologically Novel Mechanisms
Synopsis
• Creating novel protein-protein interactions to achieve therapeutic goals not achievable by otherwise targeting individual proteins
• Localizing drug to tissue or cell level of specificity
• Addressing difficult-to-drug targets
12:10 pm Session Reserved for Rapafusyn Pharmaceuticals
12:30 pm
Lunch Break & Networking
12:30 pm
One-to-One Partnering Meeting Opportunity
Why Are DACs an Attractive Technology for Pharma? Lowering Toxicity & Improving Efficacy with Increased Tissue Specificity
Why Are DACs an Attractive Technology for Pharma? Lowering Toxicity & Improving Efficacy with Increased Tissue Specificity
1:40 pm Targeted Protein Degraders as Next Generation Antibody Payloads
Synopsis
- Introducing Nurix’s expertise in targeted protein degradation and degrader-antibody conjugates
- Discussing the advantages of using degraders as antibody payloadsÂ
- Exploring collaborations
2:00 pm Precision ADCs: Engineering Novel Degrader Payloads for Improved Efficacy & Therapeutic Index
Synopsis
• Explaining key design attributes required for making TPDs effective as ADC payloads
• Approaching ADC payload optimization with a medicinal chemistry mindset
• Sharing initial proof-of-concept with a next gen anti-PSMAxSMARCA2/4 DAC for prostate cancer
2:20 pm Panel Discussion: Where do DACs Fit in? Discussing the Decision to Think about Degraders as Payloads
Synopsis
• What is it about small molecule degraders that lend themselves to making good payloads?
• Sharing parameters that allow a degrader protein to be distinct from a toxic payload
• What are some good targets for DACs?
• Collaboration potential between antibody engineering and protein degradation companies